Yu Y - Search Results

1

Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function.

Yu Y, Hoffman J, Plotka A, O'Gorman M, Shi H, Wang D. Yu Y, et al. Cancer Chemother Pharmacol. 2020 Dec;86(6):701-710. doi: 10.1007/s00280-020-04163-4. Epub 2020 Oct 10. Cancer Chemother Pharmacol. 2020. PMID: 33037918 Clinical Trial.

2

Physiologically Based Pharmacokinetic Modeling of Palbociclib.

Yu Y, Loi CM, Hoffman J, Wang D. Yu Y, et al. J Clin Pharmacol. 2017 Feb;57(2):173-184. doi: 10.1002/jcph.792. Epub 2016 Aug 22. J Clin Pharmacol. 2017. PMID: 27402157 Clinical Trial.

3

The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation.

Wang DD, Yu Y, Kassir N, Zhu M, Hanley WD, Earp JC, Chow AT, Gupta M, Hu C. Wang DD, et al. Among authors: yu y. J Clin Pharmacol. 2017 Oct;57(10):1268-1278. doi: 10.1002/jcph.921. Epub 2017 May 17. J Clin Pharmacol. 2017. PMID: 28513856

4

A Phase 1 Mass Balance Study of ¹⁴ C-Labeled Talazoparib in Patients With Advanced Solid Tumors.

Yu Y, Chung CH, Plotka A, Quinn K, Shi H, Pápai Z, Nguyen L, Wang D. Yu Y, et al. J Clin Pharmacol. 2019 Sep;59(9):1195-1203. doi: 10.1002/jcph.1415. Epub 2019 Apr 9. J Clin Pharmacol. 2019. PMID: 30964553 Clinical Trial.

5

Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.

Yu Y, Durairaj C, Shi H, Wang DD. Yu Y, et al. J Clin Pharmacol. 2020 Feb;60(2):218-228. doi: 10.1002/jcph.1520. Epub 2019 Sep 6. J Clin Pharmacol. 2020. PMID: 31489639

6

A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.

Chen W, Boras B, Sung T, Yu Y, Zheng J, Wang D, Hu W, Spilker ME, D'Argenio DZ. Chen W, et al. Among authors: yu y. J Pharmacokinet Pharmacodyn. 2020 Apr;47(2):163-182. doi: 10.1007/s10928-020-09680-6. Epub 2020 Mar 11. J Pharmacokinet Pharmacodyn. 2020. PMID: 32162138 Free PMC article.

7

Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.

Yu Y, Elmeliegy M, Litton JK, Tudor IC, Czibere A, Zheng J, Wang DD. Yu Y, et al. J Clin Pharmacol. 2020 Oct;60(10):1324-1333. doi: 10.1002/jcph.1623. Epub 2020 May 28. J Clin Pharmacol. 2020. PMID: 32468579 Clinical Trial.

8

Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.

Elmeliegy M, Yu Y, Litton JK, Czibere A, Wilson GG, Tudor IC, Zheng J, Wang DD. Elmeliegy M, et al. Among authors: yu y. J Clin Pharmacol. 2020 Oct;60(10):1334-1343. doi: 10.1002/jcph.1626. Epub 2020 May 28. J Clin Pharmacol. 2020. PMID: 32468645 Clinical Trial.

9

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib.

Zheng J, Yu Y, Durairaj C, Diéras V, Finn RS, Wang DD. Zheng J, et al. Among authors: yu y. Target Oncol. 2021 Jan;16(1):69-76. doi: 10.1007/s11523-020-00771-5. Target Oncol. 2021. PMID: 33211314 Free PMC article.

10

Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women.

Xu B, Li H, Zhang Q, Sun W, Yu Y, Li W, Wang S, Liao N, Shen P, Liu Y, Huang Y, Linn C, Zhao H, Jiang J, Wang D. Xu B, et al. Among authors: yu y. Cancer Chemother Pharmacol. 2021 Jul;88(1):131-141. doi: 10.1007/s00280-021-04263-9. Epub 2021 Apr 9. Cancer Chemother Pharmacol. 2021. PMID: 33835229 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41,470 results

Search Page

Filters